Group 1 - The global exoskeleton robot market is entering a rapid growth phase, with a projected market size of $1.8 billion in 2024 and expected to exceed $12 billion by 2030, reflecting a compound annual growth rate (CAGR) of 28% [1] - China's 14th Five-Year Plan includes exoskeletons as a key development area for high-end medical equipment, with several regions incorporating rehabilitation exoskeletons into insurance reimbursement, which is expected to accelerate commercialization [1] - The medical rehabilitation sector is seeing mature commercialization scenarios supported by policies, with a focus on three main directions: hospital policy support (innovative drugs and devices), expanding public demand (blood products, home medical devices, weight loss drug supply chain), and an upward trend in overseas market cycles (heparin, respiratory joint inspection) [1] Group 2 - The Medical ETF (159828) tracks the CSI Medical Index (code: 399989), which is compiled by the China Securities Index Co., selecting listed companies in the medical device, medical services, and pharmaceutical commercial sectors to reflect the overall performance of related securities [1] - The CSI Medical Index has strong industry representation, with the latest trading day showing an increase of 0.95%, serving as an important reference for investors looking to allocate in the healthcare industry [1] - Investors without stock accounts can consider the Guotai CSI Medical ETF Connect A (012634) and Guotai CSI Medical ETF Connect C (012635) [1]